ReviewFrontiers in immunology2025
Nanotechnology-driven platforms for extracellular vesicle analysis in tumor immunotherapy.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the most challenging diseases, the current treatment of malignant tumors has entered the era of immunotherapy. Immunotherapy has made great progress in the treatment of malignant tumors, but many patients have limited response to treatment. The search for new molecular biomarkers to evaluate the immunotherapy efficacy is particularly important. Liquid biopsy is a non-invasive method that has the advantage of providing real-time disease information to cancer patients. Extracellular vesicles (EVs), released by parental cells, contain important molecules associated with cell growth, proliferation and migration, which are regarded as the targets of liquid biopsy. In addition, EVs also participate in the information communication in tumor immune microenvironment, and are important molecular markers for monitoring the cancer immunotherapy efficacy. In this review, we summarize the challenges of conventional detection methods for EVs, and the advantages of nanotechnology detection of EVs. The important role of EVs in tumor immune microenvironment was discussed and the potential clinical significance of EVs in monitoring and predicting cancer immunotherapy response was summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.